# Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes

> **NCT02372253** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 32 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Verapamil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02372253
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-12
- **Final completion:** 2019-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372253, "Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02372253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*